Proact - German market continues to be challenging
Cancom Q2 PW and cut FY'25 EBITA guidance by -25%, stock -8%Blames reluctant customers, and particularly weak GermanyGermany is 16% for Proact, we exp...
Cancom Q2 PW and cut FY'25 EBITA guidance by -25%, stock -8%Blames reluctant customers, and particularly weak GermanyGermany is 16% for Proact, we exp...
Q2 sales lower due to customer delays amid global uncertaintyOrders strong in P&M, driven by European shore power demandMajor P&M deliveries u...
Q2e: significant decline y-o-y, but small improvements from Q1No estimate revisions on limited news flowTrading well below peers on 5x '25e EV/EBITDAS...
Orders +7%, sales -11% vs. ABGSCeEBIT adj. EUR -3m vs. ABGSCeGlobal uncertainty impacting short-lead-time ordersStronger order intake, but lower sales...
Another strong quarter with continued operational leverageAdj. EBITDA up 2-3% for '25e-'27eFair value range up to SEK 220-300 (190-270)India returns t...
+7%/+7% adj. EBITDA vs ABGSCe/cons in Q2Cons estimates likely up low- to mid-single digit on adj. EBITDA '25eOverall another strong report from Medico...
Q2 sales SEK 15m, EBIT -16m (vs. ABGSCe 37m, -9m)Temporary inventory build-up among OEM customersSEK 25m short-term loan to reduce liquidity riskSales...